Frequently Asked Questions

What skin cancers can CuradermBEC5 treat?

CuradermBEC5 is the treatment of choice for non-melanoma skin cancers including, but not limited to, Actinic Keratosis, Basal Cell Carcinoma and Squamous Cell Carcinoma. Kaposi’s Sarcoma is a cancer cause by the HIV virus, CuradermBEC5 can treat this cancer. However, CuradermBEC5 is not a recommended treatment for melanomas. CuradermBEC5 is a topical treatment and melanomas can matasisize to other internal parts of the body, which CuradermBEC5 cannot reach upon topical application. Please consult us before using CuradermBEC5 on any types of lesions that are not mentioned above.

How to use CuradermBEC5

A competent health professional should always diagnose the skin condition before Curaderm is used.

  1. Wash the lesion and the surrounding area with a mild non-irritating soap.
  2. Rinse with water
  3. Dry thoroughly
  4. Unscrew the lid of the Curaderm BEC5 tube and remove the protective foil that cover the hole in the lid of the tube.
  5. Apply Curaderm BEC5 to the Lesion, just enough to cover the lesion. Do not apply the cream in large quantity and do not extend the cream more than 0.5cm onto the apparently normal skin surrounding the edge of the lesion.
  6. Apply the cream to the lesion by gently squeezing the tube.
  7. Cover each lesion with an occlusive dressing (Micropore, Leukopor or Duoderm, not a band-aid) until the next application.
  8. Apply the cream to the lesion at least twice daily, i.e. at least every 12 hours. However, up to 10 applications with at least 0.5 hour spans can be done daily to remove the lesion more rapidly.
  9. Stop treatment only when the lesion has been completely ablated and replaced with normal skin.

What Can You Expect During Treatment with CuradermBEC5?

CuradermBEC5 contains the hydrating exfoliants salicylic acid and urea.

The purpose for these exfoliants is to remove the mass of dead cells, including the keratin layer, that pile up above skin cancer that has not yet pushed itself up on the surface of the skin.

Cancer cells are alive and originate in the living, dividing skin cells and are generally covered by the superficial dead skin cells. Salicylic acid and urea help remove the outer layer surface of dead cells so that BEC is accessible to interact and kill the cancer cells. BEC at the concentration used, does not kill normal cells.

In the initial stages of CuradermBEC5 therapy, which may vary from one day to several weeks depending on size and type of cancer, the treated lesion will become larger. The reaction of the tumour treated with CuradermBEC5 may be unsightly at the initial stages during treatment.

The reason for the initial increase in lesion size is that CuradermBEC5 is seeking and destroying the cancer cells that are originally not visible to the naked eye. At this stage some patients may be discouraged to continue treatment because the cancer seems to be getting worse and not better. In addition, some patients may experience pain or a burning sensation for some time after CuradermBEC5 is applied to the lesion.

These possible observations are all part of the treatment regime. Don't forget we are dealing with cancer. The possible pain experienced, is due to the salicylic and urea contents and not the active ingredient BEC. Salicylic acid and urea help with the penetration of BEC to kill the deep-seated cancer cells.

After some time during the treatment, the lesion will start to reduce in size. At this stage most of the cancer cells are eliminated by the treatment. Treatment should continue and because the lesion is becoming smaller, less CuradermBEC5 cream is applied to the lesion.

Treatment should continue until the lesion is completely gone and replaced with normal skin. If treatment is stopped too early, some residual cancer cells may remain and over time will become a lesion again. Studies have shown if the procedure is followed diligently, all cancer cells are removed and the lesion will be eradicated with no recurrences.